Hypertension Part 2 | Harrison Simplified скачать в хорошем качестве

Hypertension Part 2 | Harrison Simplified

This video provides a comprehensive and structured overview of hypertension management, based on Harrison’s Principles of Internal Medicine, 22nd edition. ⚠️ Important note: This is a detailed and in-depth management video. It is recommended to watch it once carefully to build a strong conceptual understanding of hypertension management. A separate summary/revision video will be prepared later for quick review. 00:00 – 01:06 | Introduction & Core Management 01:07 – 03:04 | Diagnostic Criteria & Staging of Hypertension 🧘 Non-Pharmacological Management 03:05 – 06:08 | Overview of Lifestyle Interventions 03:21 – 03:58 | DASH Diet 04:00 – 04:20 | Weight Loss 04:22 – 04:49 | Salt Restriction 05:00 – 05:31 | Potassium Supplementation 05:33 – 05:59 | Physical Activity 06:00 – 06:08 | Alcohol Reduction 06:09 – 06:47 | Synergy of Lifestyle Changes & Clinical Application 📜 Background & Evidence 06:48 – 08:48 | Historical Context of Hypertension Treatment 08:49 – 10:04 | Meta-analysis Data & Treatment Benefits 💊 Pharmacological Therapy 10:05 – 11:27 | Five Core Classes of Antihypertensive Drugs Diuretics 11:28 – 13:55 | Thiazide & Thiazide-like Diuretics 12:00 – 13:20 | Chlorthalidone vs HCTZ 13:21 – 13:55 | Adverse Effects RAAS Blockers (ACEi & ARBs) 13:56 – 16:40 | Clinical Use & Safety 14:16 – 14:38 | Mechanism of Action 15:25 – 15:53 | ACE Inhibitor–Induced Cough 15:55 – 16:40 | Safety Warnings Calcium Channel Blockers 16:41 – 18:13 | CCBs Overview 17:08 – 17:59 | Dihydropyridines (DHPs) 18:00 – 18:13 | Non-Dihydropyridines Beta Blockers 19:26 – 21:11 | Role in Hypertension 19:35 – 20:05 | Why Beta-Blockers Are Inferior as First-Line 20:06 – 20:45 | Generations of Beta-Blockers 20:51 – 21:11 | Specific Clinical Indications 🔗 Treatment Strategy 21:12 – 23:19 | Combination Therapy Approach 21:48 – 22:30 | Initial Treatment Selection 22:31 – 22:50 | Minimizing Side Effects 22:51 – 23:19 | Best Drug Combinations 23:21 – 23:42 | Single-Pill Combinations 23:43 – 24:09 | Expected Number of Drugs to Reach Goal 24:10 – 24:58 | Therapeutic Inertia 🎯 Blood Pressure Targets 24:59 – 26:40 | Ideal BP Goals & Evidence (SPRINT Trial) Earlier editions of Harrison highlighted concerns about excessive blood pressure lowering suggesting a potential increase in cardiovascular risk with very low BP—especially low diastolic pressure. However, recent randomized trials, most notably the SPRINT trial, demonstrated that intensive systolic BP control improves cardiovascular outcomes and reduces mortality, provided diastolic hypotension is avoided. Current guidelines therefore recommend a target blood pressure of less than 130/80 mmHg for most patients. 👥 Special Populations 26:41 – 35:59 | Hypertension in Special Populations 26:52 – 27:29 | Cardiovascular Disease (CAD, HF, Stroke) 27:30 – 28:49 | Diabetes Mellitus 28:50 – 31:23 | Chronic Kidney Disease (CKD) 31:24 – 33:34 | Elderly Patients 33:35 – 35:17 | Non-Hispanic Black Adults 35:18 – 35:59 | Sex Differences 🚨 Resistant Hypertension 36:00 – 37:34 | Resistant Hypertension 36:07 – 36:23 | Definition 36:24 – 37:34 | Ruling Out Pseudo-Resistance 🎯 Target audience: Medical students, interns, residents, and clinicians seeking a clear, logical, and exam-relevant approach to hypertension management. 💬 Feel free to leave questions or topic requests in the comments . PDF SLIDES https://drive.google.com/file/d/1DxxJ...